Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1993-3-17
|
pubmed:abstractText |
TRH stimulation tests (n = 1109) were performed on 1061 ambulatory and 43 hospitalized patients with varying thyroid status, using a TSH immunochemiluminometric assay with third and fourth generation sensitivity characteristics (functional sensitivity, 0.01 and 0.001 mU/L, respectively). TRH test results were analyzed as both absolute (stimulated minus basal TSH) and fold (stimulated/basal TSH) responses. The absolute TRH response varied 8-fold across the physiological TSH range, whereas the mean fold response remained almost constant (mean +/- SEM, 8.5 +/- 0.2). The fold response became progressively attenuated as basal TSH values declined below physiological levels, becoming essentially absent in clinically thyrotoxic patients with markedly depressed basal serum TSH levels (0.007 +/- 0.002 mU/L). Progressive attenuation also occurred at hypothyroid TSH levels; a markedly impaired fold response (2.5 +/- 0.4) was characteristic of primary hypothyroid patients with basal TSH values greater than 50 mU/L. In untreated central hypothyroid patients with near-normal basal TSH levels, the TRH fold response was impaired (1.7 +/- 0.2), whereas in T4-replaced central hypothyroid patients, fold responses were near normal (5.6 +/- 1.2). Neither nonthyroidal illness, age, or sex appeared to influence the pattern of fold TRH response in the populations evaluated. When using third and fourth generation TSH methodology, the TRH-stimulated TSH fold response is more diagnostically useful than the absolute TRH response. However, if patients have an intact hypothalamic-pituitary axis, there appears to be no diagnostic advantage gained by TRH testing over an accurately measured basal TSH value.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0021-972X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
76
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
494-8
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:8432796-Adult,
pubmed-meshheading:8432796-Female,
pubmed-meshheading:8432796-Graves Disease,
pubmed-meshheading:8432796-Humans,
pubmed-meshheading:8432796-Hypothyroidism,
pubmed-meshheading:8432796-Immunoassay,
pubmed-meshheading:8432796-Luminescent Measurements,
pubmed-meshheading:8432796-Male,
pubmed-meshheading:8432796-Middle Aged,
pubmed-meshheading:8432796-Reference Values,
pubmed-meshheading:8432796-Thyroid Diseases,
pubmed-meshheading:8432796-Thyroid Function Tests,
pubmed-meshheading:8432796-Thyrotropin,
pubmed-meshheading:8432796-Thyrotropin-Releasing Hormone,
pubmed-meshheading:8432796-Thyroxine
|
pubmed:year |
1993
|
pubmed:articleTitle |
Thyrotropin (TSH)-releasing hormone stimulation test responses employing third and fourth generation TSH assays.
|
pubmed:affiliation |
Department of Medicine, University of Southern California School of Medicine, Los Angeles 90033.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|